Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics will present early-stage cancer drug data at SITC 2026 next week.

What the company is saying

Werewolf Therapeutics is announcing its selection for an oral presentation and two poster sessions at the Society for Immunotherapy of Cancer’s 2026 Annual Meeting, emphasizing external scientific validation of its clinical-stage pipeline. The company highlights two product candidates: WTX-124, a tumor-activated IL-2 prodrug, and WTX-330, a tumor-activated IL-12 prodrug, both designed to stimulate the immune system against solid tumors. The announcement details the titles, abstract numbers, session times, and venues for each presentation, with Justin Moser, M.D. of HonorHealth Research Institute named as the oral session presenter. The company frames its technology as innovative, using language about conditionally activated therapeutics and selective tumor microenvironment activation, but does not present any efficacy or safety data. The tone is factual and focused on scientific engagement rather than commercial or financial progress. Jonathan Owen is listed as SVP, General Counsel and Secretary, but no executive commentary or forward-looking financial statements are included.

What the data suggests

The announcement provides concrete details about Werewolf Therapeutics’ participation at SITC 2026, including exact dates (November 4-8, 2026), presentation times, and session locations. The oral presentation on WTX-124 is scheduled for November 7, 2026, from 2:30-2:45 p.m. MT, and the poster on WTX-330 will be displayed the same day from 9 a.m. to 8:30 p.m. MT. Both programs are described as clinical-stage, but no trial results, enrollment numbers, or clinical endpoints are disclosed. The company’s INDUKINE platform is described in mechanistic terms, but there is no supporting experimental or clinical data in this release. No financial, operational, or business performance metrics are included. The disclosure is complete for conference logistics but does not provide evidence of clinical or commercial progress.

Analysis

The announcement is a factual disclosure of Werewolf Therapeutics' participation in the SITC 2026 Annual Meeting, listing specific presentation titles, times, and presenters. There are no claims of clinical results, financial performance, or operational milestones—only the logistics of upcoming scientific presentations. The only forward-looking statements are generic descriptions of the intended mechanism and therapeutic goals of the company's product candidates, which are standard in biotech conference notices and not presented as imminent achievements. No capital outlay, revenue, or profitability data are disclosed, nor are there any claims of near-term or long-term benefit realization. The language is proportionate to the content, with no evidence of narrative inflation or overstatement.

Risk flags

• ●There is no disclosure of clinical results, so the efficacy and safety profile of WTX-124 and WTX-330 remain unproven, leaving significant uncertainty about the likelihood of future development success.
• ●The announcement provides no financial data or operational milestones, making it impossible to assess the company’s cash runway, burn rate, or ability to fund ongoing trials, which is a material risk for pre-revenue biopharmaceutical companies.
• ●The company’s claims about selective activation and immune stimulation are stated as intended mechanisms without supporting data, raising the risk that the technology may not perform as described in human studies.

Bottom line

This announcement signals that Werewolf Therapeutics will present early-stage clinical data for its two lead cancer immunotherapy candidates, WTX-124 and WTX-330, at a major scientific conference next week. The disclosure is limited to presentation logistics and high-level mechanistic claims, with no clinical results or financial information provided. Investors should recognize that the core value driver will be the actual data presented at SITC, which is not previewed here. The absence of efficacy, safety, or operational updates means this release does not change the risk/reward profile or provide new evidence of progress. The most important takeaway is that the next catalyst will be the substance of the SITC presentations, not the fact of conference participation itself.

Announcement summary

(NASDAQ:HOWL) Werewolf Therapeutics, Inc. announced that it has been selected for an oral presentation and will present two posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, which will take place from November 4-8, 2026, in Phoenix, Arizona. The oral presentation is titled 'A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors.' The oral presentation has been assigned Abstract Number 1189. The presenter for the oral session is Justin Moser, M.D., from HonorHealth Research Institute. The oral presentation is scheduled for Saturday, November 7, 2026, from 2:30-2:45 p.m. MT, in the North Building - 300 Level – Halls BC, during Session 205: Clinical Oral Abstract Session 2, which runs from 1:30-3:00 p.m. MT. Werewolf Therapeutics will also present a poster titled 'A Phase 1b/2 study of the tumor-activated IL-12 prodrug WTX-330 in patients with relapsed/refractory solid tumors.' The poster has been assigned Abstract Number 494. The poster session will take place on Saturday, November 7, 2026, from 9 a.m.–8:30 p.m. MT, in the North Building - Lower Level – Exhibition Halls 4-6. Werewolf Therapeutics’ clinical stage product candidates include WTX-124, a systemically delivered, conditionally activated Interleukin-2 INDUKINE molecule, and WTX-330, a systemically delivered, conditionally activated Interleukin-12 INDUKINE molecule, both for the treatment of solid tumors. The company’s INDUKINE molecules are designed to stimulate both adaptive and innate immunity and are intended to remain inactive in peripheral tissue but activate selectively in the tumor microenvironment. Jonathan Owen is listed as SVP, General Counsel and Secretary of Werewolf Therapeutics.

Disagree with this article?